Bullish indicating open at $55-$60, IPO prices at $37
Enfusion , Inc. (NYSE:ENFN) Chief Operating Officer Neal Pawar recently sold 2,769 shares of the company’s Class A Common Stock. The shares were sold on March 3 at an average price of $11.481, totaling approximately $31,790. The transaction comes as Enfusion trades near its 52-week high of $11.80, having gained over 41% in the past six months. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 3.42.
This transaction was made to cover tax withholding obligations related to the issuance of shares, according to the company. Following the sale, Pawar retains direct ownership of 1,231,627 shares of Enfusion, demonstrating continued significant insider stake in the $1.47 billion market cap company.
These shares were sold in multiple transactions with prices ranging from $11.429 to $11.535. The detailed breakdown of these transactions is available to the Securities and Exchange Commission upon request. For deeper insights into Enfusion’s valuation and financial health metrics, access the comprehensive Pro Research Report available on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable intelligence.
In other recent news, Enfusion Inc has announced its fourth-quarter earnings for 2024, which coincided with the company’s acquisition agreement with Clearwater Analytics. The acquisition is set at $11.25 per share, a price that now serves as a benchmark for analysts and investors. Stifel analysts have maintained a Hold rating on Enfusion, aligning their price target with the acquisition price of $11.25, suggesting limited deviation from this valuation. Morgan Stanley (NYSE:MS) also adjusted its stance, downgrading Enfusion from Overweight to Equal-weight, while increasing the price target to match the acquisition offer. The acquisition by Clearwater is seen as a means to expedite value realization for shareholders, addressing past concerns about Enfusion’s public float and market dependencies. Stifel had previously downgraded Enfusion from Buy to Hold, aligning its price target with the acquisition price, which is a 13% premium over the stock’s previous closing price. The acquisition values Enfusion at approximately 6.4 times its projected FY25 enterprise value/revenue. Analysts from both firms indicate that the acquisition price is fair, with little expectation of a higher competing bid.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.